IFNG and neoplasm: Taking advantage of the observations that (1) NF-κB protects cells from IFN-γ, (2) NF-κB is a survival factor in RCC, and (3) one mechanism by which bortezomib mediates its anti-tumor effects is by inhibiting NF-κB, we have found in preliminary experiments that bortezomib renders a panel of RCC cell lines susceptible to IFN-γ-induced necrosis at doses of each agent that are physiologically very achievable (RJT, PC, and SB, unpublished data).